The Balancing Act® airing on Lifetime TV Talks New Options for Breast Cancer Patients
Breast Cancer Awareness Month Programming Features DARA BioSciences Inc. and New York Breast Reconstruction Alliance hosted by Julie Moran on October 14th Show
(Pompano Beach, FL – CISION – October 9, 2013) Popular morning show The Balancing Act® airing on Lifetime TV welcomes two companies dedicated to providing new options for breast cancer patients to the show airing on Monday, October 14 at 7:00 a.m. (ET/PT) as part of Breast Cancer Awareness Month Programming. Make sure to tune in as The Balancing Act hosts help jump start the day with animated conversation and trusted information to empower a woman’s life.
Don’t miss these featured segments taking center stage on The Balancing Act®:
- Breast Reconstruction: What You Need to Know with New York Breast Reconstruction Alliance
The fact is that 7 out of 10 women in this country are not even aware that breast reconstruction exists is an option, with only 20% of women who undergo mastectomy going on to have reconstruction. And the good news is that breast reconstruction is covered by most health insurance plans. Join Dr. Randall Feingold, Plastic Surgeon and Founder of the New York Breast Reconstruction Alliance, as he discusses the latest groundbreaking techniques in breast reconstruction and comprehensive resources available for education and patient care for women and their families. Also joining the show is Kim Dresch, a breast cancer survivor who shares her inspiring story and advocacy efforts. www.nybra.com www.breastreconstruction.org
- New Options for Breast Cancer Patients, supported by DARA BioSciences Inc.
Breast cancer: Approximately one in eight American women will develop breast cancer during their lifetime, so chances are you know someone who has been touched by the disease or possibly experience breast cancer yourself. Join Nancy Peacock, MD, a breast cancer specialist from Tennessee Oncology, and Julie Megee, breast cancer survivor, for an in-depth discussion regarding the importance of patient compliance to tamoxifen therapy and how Soltamox® (tamoxifen citrate) oral solution may help compliance in patients who prefer or need a liquid formulation. The guests also discuss other supportive care issues, including how the painful symptoms of oral mucositis caused by radiation treatment and chemotherapy may be relieved by Gelclair®, an oral rinse gel, as well as the role of Bionect® topical ointment in helping to alleviate radiation-induced skin irritation and burns.
This educational segment on breast cancer is sponsored by DARA BioSciences, an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment. DARA holds US marketing rights to Soltamox®, the only FDA-approved liquid form of tamoxifen, which is widely used for the treatment and prevention of breast cancer. The company also markets Gelclair®, a bioadherent oral rinse gel for relief of oral mucositis pain caused by chemotherapy and radiation treatment, and Bionect® (hyaluronic acid sodium salt, 0.2%), a topical treatment for skin irritation and burns, in US oncology/radiology markets.
Please see Soltamox® (tamoxifen citrate) Important Safety Information and the Black Box Warning, below. For full Prescribing Information and the complete Black Box warning visit www.soltamox.com.
For additional information on DARA BioSciences and its products visit www.Darabio.com, www.Gelcliar.com www.Soltamox.com and www.bionect.com.
“We are pleased to partner with The Balancing Act® to produce this educational segment about breast cancer treatment and support, and appreciate The Balancing Act’s commitment to breast cancer education and programming during Breast Cancer Awareness Month,” said David J. Drutz, MD, DARA's chief executive officer and chief medical officer. “We are grateful to Dr. Peacock and Ms. Megee for sharing their experiences on national television, so that others may learn from their insights and knowledge.”
IMPORTANT SAFETY INFORMATION
Tamoxifen citrate is contraindicated in patients with known hypersensitivity and also in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. If hypercalcemia does occur, appropriate measures should be taken and, if severe, tamoxifen should be discontinued. There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy. When tamoxifen is coadministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. Adverse reactions to tamoxifen are relatively mild and rarely severe enough to require discontinuation of treatment in breast cancer patients.
WARNING
In Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer Serious and life-threatening events were associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women). Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-855-273 0468
About The Balancing Act® on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple - the show strives to help today’s modern woman balance it all by bringing them exceptional solutions to everyday problems. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings at 7:00 am (ET/PT) on Lifetime television.
For additional information or to view a segment visit: www.thebalancingact.com
Join the Conversation!
Like us on Facebook
Follow us on Twitter
Watch us on YouTube
Media Contact:
O2 Media, Inc.
pamela@o2mediainc.com
(954) 691-1102
Tags:
